Reducing the Rebate Amount for Part B Rebatable Biosimilar Biological Products When There Is a Severe Supply Chain Disruption In 427.402 of this proposed rule, CMS proposes to codify the policy established in section 50.12 of the revised Medicare Part B Drug Inflation Rebate Guidance for rebate reductions when CMS determines there is a severe supply chain disruption during a calendar quarter
CMS understands that generic drugs are often low-margin products whose prices are tied to the marginal cost of production and thus are vulnerable to potential market exit and shortage when input costs increase
In the CY 2024 PFS final rule (88 FR 79513), we compared the performance of clinicians who received the complex patient bonus with our overall population
Hukkanen, J., Jacob, P
In the agencys statement, the FDA promised that the ban will only target manufacturers, distributors, wholesalers, importers and retailers of menthol products
The liver, in particular, is responsible for metabolizing and detoxifying substances, including nicotine and other chemicals found in cigarettes